The global central nervous therapeutics market is expected to grow at a CAGR of 7.5% during the forecast. The growing number of central nervous disorders across the globe is significantly contributing to the growth of the global central nervous system therapeutic market. The prevalence of Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease, mental health and stroke are significantly growing across the globe. For instance, as per the World Health Organization (WHO), epilepsy is a chronic non-communicable disease of the brain which affects the brain around 50 million people across the globe are suffering from this disease and is one of the most common neurological diseases. Depression is a common mental disorder, around 5% of adults across the globe suffered from depression. It is a leading cause of disability across the globe. This, in turn, is driving the demand for treatment for these disorders, which in turn, is accelerating the market growth.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/central-nervous-system-therapeutic-market
Some new launches of CNS drugs have been witnessed across the globe. For instance, in April 2021, Optimus Pharma announced that it has received approval for its Anti-Parkinson drug Safinamide in India. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. Optimus believes Safinamide will give an additional option to healthcare professionals in the treatment of Parkinson’s and improve the quality of life of millions who are affected by Parkinson’s disease. A homegrown generic version of Safinamide developed by Optimus will assist in delivering robust treatment for Parkinson’s diseases in India with very high affordability and accessibility.
Global Çentral Nervous Therapeutic Market Report by Segment
By Indication
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Neurodegenerative Diseases
- Infectious Diseases
- Cancer
By Application
- Hospital & Clinic
- Homecare
- Others
By Drug Class
- Immunomodulatory Drugs
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Antidepressants
- Others
A full report of Central Nervous System Therapeutic Market is available at: https://www.omrglobal.com/industry-reports/central-nervous-system-therapeutic-market
Central Nervous System Therapeutic Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca plc
- Cipla Ltd.
- CNS Pharmaceuticals, Inc.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Lundbeck A/S
- Lupin Ltd.
- Medopharm Private Ltd.
- Neurelis, Inc.
- Nuventra Pharma Sciences
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Sanofi S.A.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
Visit more report at
https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/
